ArticleScientific reports2026
SHP2 improves ovarian morphology and steroidogenic function in a rat PCOS model by modulating IRE1α/XBP1/NLRP3-mediated granulosa cell pyroptosis.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The specific role and mechanism of SHP2 in polycystic ovary syndrome (PCOS) remain unclear. This study aimed to evaluate the therapeutic potential of SHP2 and elucidate the signaling pathways through which it modulates granulosa cell fate in PCOS. A PCOS rat model was established via letrozole administration. Rats were divided into three groups (n = 6 each): Sham, Model, and SHP2-overexpressing (SHP2-OE). The SHP2-OE group received lentiviral injection prior to modeling. Ovarian histopathology was assessed using Hematoxylin and Eosin (HE) staining. Serum sex hormones were measured by ELISA. Western blotting was used to detect the protein expression of the IRE1α/XBP1/NLRP3 and ZEB1/PKP3 signaling pathways in granulosa cells after different stimulations. Flow cytometry was used to detect granulosa cell apoptosis. In vivo, SHP2 overexpression significantly ameliorated PCOS-induced ovarian damage, characterized by reduced ovarian weight, fewer cystic follicles, and increased corpora lutea. Hormonally, SHP2-OE decreased levels of estradiol, testosterone, and luteinizing hormone, while increasing follicle-stimulating hormone. Mechanistically, in vitro analysis revealed that testosterone treatment inhibited SHP2 phosphorylation and downregulated PKP3, nuclear E2F1, and CyclinB1. In addition to addition, testosterone activated the IRE1α/XBP1/NLRP3 and ZEB1 pathways, upregulating p-IRE1α, XBP-1s, p-SP1, ZEB1, NLRP3, and GSDMD, thereby promoting granulosa cell apoptosis and pyroptosis. SHP2 alleviates PCOS-related reproductive endocrine abnormalities and ovarian pathological changes by regulating the IRE1α/XBP1/NLRP3 and ZEB1/PKP3 signaling pathways, thereby influencing granulosa cell pyroptosis and proliferation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.